Acarbose: oral antidiabetes drug with additional cardiovascular benefits

Authors: Hanefeld, Markolf; Schaper, Frank

Source: Expert Review of Cardiovascular Therapy, Volume 6, Number 2, February 2008 , pp. 153-163(11)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Acarbose is an α-glucosidase inhibitor acting specifically at the level of postprandial glucose excursion. This compound lowers HbA_1c by 0.5-1% in patients with Type 2 diabetes, either drug naive or in combination with other antidiabetic drugs. In those with impaired glucose tolerance (IGT), it reduces the incidence of newly diagnosed diabetes by 36.4%. Furthermore, it has beneficial effects on overweight, reduces blood pressure and triglycerides, and downregulates biomarkers of low-grade inflammation. In the Study To Prevent Non-Insulin-Dependent-Diabetes-Mellitus (STOP-NIDDM) trial, acarbose significantly reduced the progression of intima media thickness, incidence of cardiovascular events and of newly diagnosed hypertension. In a meta-analysis of patients with Type 2 diabetes (MERIA), acarbose intake was associated with a reduction of cardiovascular events by 35%. Acarbose is a very safe drug but in approximately 30% of patients, it can cause gastrointestinal complaints due to its mode of action, which in the majority disappear after 1-2 months. Acarbose is approved for treatment of IGT in 25 countries. It can be given alone or in combination with other oral antidiabetics and insulin. Acarbose is particularly effective in those with IGT and early diabetes and patients with comorbidities of the metabolic syndrome.

Keywords: acarbose; cardiovascular disease; impaired glucose tolerance; prevention; Type 2 diabetes

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14779072.6.2.153

Affiliations: 1: Centre for Clinical Studies, Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany., Email: hanefeld@gwtonline-zks.de

Publication date: 2008-02-01

More about this publication?

Expert Review of Cardiovascular Therapy provides expert commentary on the clinical applications of the new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage inculdes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites

Acarbose: oral antidiabetes drug with additional cardiovascular benefits

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages